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Abstract 
 Cachexia is a multifactorial syndrome characterized by body weight loss, depletion of 
adipose tissue and skeletal muscle mass, and marked alterations of the metabolic homeostasis. 
The occurrence of cachexia significantly impinges on patient's morbidity and mortality, and on 
quality of life. Inflammation, anorexia/malnutrition, alterations of protein and lipid metabolism are 
among the main mechanisms involved in the development of cachexia. While anorexia and 
malnutrition are long known contributing factors, the mechanisms leading to inflammation and 
metabolic alterations were clarified later on. On these premises, several therapeutic approaches 
were proposed. Most of them are in the pre-clinical phase, but some already reached the clinical 
experimentation. The present review will focus on treatment options proposed on the basis of 
mechanistic alterations. In this regard, in addition to nutritional and anti-inflammatory strategies, 
also approaches based on perturbation of specific signal transduction pathways are taken into 
consideration. 
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Introduction 
 Chronic pathologies such as diabetes, cancer, congestive heart failure, autoimmune or 
neurological diseases, result in a significant impairment of patients’ quality of life. Indeed, in 
addition to features specific to each disease, patients frequently show marked alterations of whole 
body homeostasis, that ultimately result in tissue wasting, impaired nutritional status and reduced 
ability to perform daily activities. This condition, termed as cachexia, is often disregarded until it 
becomes clinically evident. Unfortunately, at this point it is also barely responsive to the few 
treatments available, most of which, however, are merely symptomatic. In this regard, early 
targeted interventions have been proposed to be helpful in preventing the progression of cachexia 
form a 'latent' to an 'overt' condition. Indeed, once a sort of no-return point is reached, the balance 
among several components contributing to disease-induced derangement is likely to get lost, and 
no intervention can be successful anymore. These observations put in evidence the urgent need of 
biomarkers suitable to detect the condition of 'latent' cachexia.  
 Few years ago a couple of papers reported a definition of cachexia (Evans et al., 2008; 
Muscaritoli et al., 2010): 'Cachexia may be defined as a multifactorial 
syndrome characterized by severe body weight, fat and muscle loss and increased protein 
catabolism due to underlying disease(s). Cachexia is clinically relevant since it increases patients’ 
morbidity and mortality. Contributory factors to the onset of cachexia are anorexia and metabolic 
alterations, i.e. increased inflammatory status, increased muscle proteolysis, impaired 
carbohydrate, protein and lipid metabolism' (quoted from Muscaritoli et al., 2010). Such efforts in 
defining cachexia are particularly relevant especially in view of identifying populations of patients in 
which the syndrome is more likely to develop. In this regard, a three stage classification of 
cachexia has been recently proposed: precachexia, cachexia, and refractory cachexia (Fearon et 
al., 2011). Due to the complex etiology of this syndrome, the assessment of cachexia should 
include several parameters, such as the occurrence of anorexia and malnutrition, the loss of body 
weight, the depletion of adipose tissue, the loss of muscle mass and strength, the activation of 
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hypercatabolism, the presence of a chronic inflammatory state, and last, but not least, the impact 
that cachexia exerts on the patient.  
 
Body and tissue wasting 
 The loss of body weight is one of the hallmarks of cachexia. While its pathogenesis may be 
different, going from simple caloric restriction to the profound derangements observed in cancer 
patients, its occurrence often associates with worse prognosis and poor tolerance to therapies. 
This is particularly evident in cancer patients, where weight loss has been reported in about 50% to 
70% of new diagnosis (Muscaritoli et al., 2006). Neoplastic patients presenting with weight loss 
before the beginning of treatments often show poor tolerance to surgery, chemotherapy, and 
radiotherapy. By contrast, a good performance status positively correlates with tolerance and 
response rates to chemotherapy and radiotherapy, and with survival (Tan and Fearon, 2008). In 
this regard, particular attention should be given to patients in which body weight loss could be 
masked, such as those presenting with water retention (cancer, liver chirrhosis, heart or renal 
failure), or obesity. 
 Body weight loss mainly results from reduced adipose tissue and/or skeletal muscle mass. 
This latter should be regarded as the main feature of ongoing cachexia, for the following reasons: 
firstly, muscle mass below 50% of body weight is not compatible with survival (Wolfe, 2006, and 
references therein), and, secondly, the adipose tissue may not be affected early, at least in 
neoplastic patients. Consistently, obese cancer patients frequently show significant muscle 
depletion in face of elevated body mass index and maintenance of adipose tissue mass 
(sarcopenic obesity; Prado et al., 2008; Stenholm et al., 2008). Not only, the increase in fat in 
obese subjects masks the occurrence of lean body mass, in particular in the early stages of the 
disease, thus delaying the adoption of specific metabolic interventions. The different kinetic of 
depletion in muscle and fat, however, should not divert the attention from the latter. Indeed, many 
years ago Argilés and coworkers (2005) proposed the existence of a cross talk between the two 
tissue compartments. Such hypothesis has been clearly demonstrated in a recent report (Das et 
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al., 2011), showing that inhibition of lipolysis in tumor-bearing mice by genetic ablation of lipolytic 
enzymes prevents hyperlipidemia and adipose mass depletion, but also skeletal muscle wasting.  
 Irrespective of the underlying disease, the skeletal muscle, which accounts for 
approximately half of the body protein mass, is severely affected in cachexia. Skeletal muscle is a 
very heterogeneous tissue, in charge of several biological functions such as movement, stability, 
heat production and cold tolerance. Considered in the past as a mere protein reservoir, it is now 
recognized to release cytokines and other humoral factors (Pedersen & Febbraio, 2008).  Since 
the skeletal muscle plays a pivotal role in the overall energy balance, regulating lipid flux, plasma 
glucose storage, and insulin sensitivity, it participates in the control of whole body metabolism, also 
acting in concert with the adipose tissue. The main factor regulating skeletal muscle mass is 
protein content, that strictly depends on the balance between synthesis and degradation rates. 
Physiologically, in the adult individual protein synthesis does not exceed degradation, and vice-
versa, allowing the maintenance of the skeletal muscle mass. Generally speaking, modulations of 
both sides of turnover eventually converge to produce a new steady-state. In this regard, enhanced 
protein synthesis, which responds earlier than degradation to the inducing stimuli, mainly results in 
muscle hypertrophy, while protein hypercatabolism leads to muscle depletion. 
 
Anorexia 
 Defined as reduced desire to eat and early satiety, anorexia leads to decreased number of 
meals during the day and reduced amount of food consumed in each meal. It is a frequent feature 
of chronic pathologies, although it is often not recognized and left untreated, thus significantly 
contributing to malnutrition. In this regard, food intake in patients should be accurately and 
routinely monitored, in order to immediately identify a change from the usual habit. At least in 
cancer patients, tools such as the Functional Assessment of Anorexia/Cachexia Therapy and the 
North Central Cancer Treatment Group Anorexia/Cachexia can provide a qualitative and 
quantitative assessment of anorexia (Muscaritoli et al., 2010).  
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 In addition to alterations in the central control of eating, secondary causes of reduced food 
intake may be constipation, stomatitis, pain and depression. From a therapeutic point of view, the 
mechanisms underlying anorexia in the different patients should be readily identified, in order to 
adopt the most correct approach. To recognize the occurrence of anorexia may be relevant also in 
view of the fact that early satiety correlates with worse outcome, at least in cancer patients (Walsh 
et al., 2002).  
 The altered control of eating behavior mainly depends on pro-inflammatory cytokines (TNF-
α, IL-6 and IL-1). Such mediators, directly, or indirectly through modulations of the physiological 
levels of several neuropeptides (leptin, neuropeptide Y, melanocortin, agouti-related peptides), 
modify appetite and metabolic rate. More specifically, cytokine bioactivity results in induction of 
anorexigenic pathways and inhibition of the orexigenic ones, leading to appetite loss and increased 
satiety (Grossberg et al., 2010).  
 The occurrence of anorexia may contribute to explain the loss of body weight that 
characterizes patients affected by chronic diseases. However, at least in cancer cachexia, weight 
loss generally differs from that due to simple food deprivation. During caloric restriction, indeed, 
initially glucose and aminoacids are mobilized from the liver, fat becoming the primary energy 
source later on, in order to preserve tissue protein. By contrast, patients with cancer cachexia fail 
to turn metabolism into a protein-sparing setting, resulting in a persistently negative nitrogen 
balance which defies a purely nutritional correction (Laviano et al., 2003, Lancet Oncol). 
 
Inflammation 
 Inflammation is a tightly regulated mechanism aimed at protecting the organism against 
alterations of the homeostasis due to different stimuli such as biological, physical or chemical 
agents on one side, and damaged, infected, or neoplastic cells on the other. The inflammatory 
response is generally endowed with self-regulation properties, achieved through a complex 
network including both inflammatory/immune cells and humoral mediators, that regulates the 
equilibrium between pro-inflammatory and anti-inflammatory stimuli. When the balance between 
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pro- and anti-inflammatory response is persistently lost, chronic inflammation occurs. This was 
suggested to significantly contribute to the pathogenesis of several chronic illnesses such as 
autoimmune and neurodegenerative diseases, diabetes and its complications, cancer, AIDS, 
obesity. In this regard, all these pathological states are associated with increased circulating levels 
of pro-inflammatory mediators. As an example, IL-6, TNF and TNF soluble receptors are 
detectable in patients affected by chronic heart or renal failure (Li et al., 2011; Niewczas et al., 
2012). In these latter, increased levels of acute phase reactants correlate with increased mortality 
(Noori et al., 2011). Similarly, pro-inflammatory cytokines such as TNF, IL-6, -INF, LIF are 
increased also in cachectic neoplastic patients (reviewed by Seruga et al., 2008).  
The link between cancer and inflammation was proposed by Virchow already in the 19th 
century (the Virchow hypothesis; Durham et al., 2009), and again after the discovery of the first 
cytokines (see Winfield et al., 2008). In 1972 Prehn demonstrated that immune cells in tumor 
stroma, such as M2 macrophages, Treg lymphocytes, dendritic cells, promote tumor growth. 
Indeed, inflammation plays a dual role: it is involved in carcinogenesis and tumor progression, but 
also in the metabolic derangements induced in the patient by the presence of the tumor. Recently, 
the relation between the acute phase response (systemic inflammation) and cancer cachexia was 
proposed from the observation that enhanced liver protein synthesis could drive muscle protein 
hypercatabolism  contributing to the elevated resting energy expenditure (Durham et al., 2009). Not 
only, the skeletal muscle itself was proposed as a source of acute phase reactants, likely diverting 
aminoacids from the synthesis of structural proteins to that of acute phase mediators (Bonetto et 
al., 2011). Of interest, acute phase proteins are further increased by nutritional supplementation, 
suggesting that anti-inflammatory treatments should be included in the therapeutic protocol 
(Stephens et al., 2008). Systemic inflammation appears correlated with reduced survival. Indeed, 
cancer patients with high CRP levels survive less than those with low/normal levels (Stephens et 
al., 2008). In some studies survival is more accurately predicted by CRP levels than by tumor 
stage (Stephens et al., 2008). In this regard, CRP is used to provide scores suitable for the clinical 
use, such as the Glasgow prognostic score that couples increased CRP ( 10 mg/l) and 
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hypoalbuminemia (  35 mg/l); CRP and white blood cells; CRP ( 10 mg/l), body weight loss ( 
10%), reduced food intake ( 1500 kcal/day; Fearon et al., 2006).  
 Another good example of inflammation-driven disease is diabetes. Hyperglycemia, indeed, 
leads to the production and accumulation of advanced glycation end-products (AGE), known to 
induce inflammatory reactions. AGE accumulation leads to oxidative stress increasing the risk of 
diabetes complications such as hypertension, neuropathy, nephropathy and retinopathy, as well as 
the risk of cancer development (Nienhuis et al., 2009). In addition, at least type II diabetes is 
frequently associated with obesity, another pro-inflammatory condition (de Heredia et al., 2012). 
 In the last years, several signaling pathways, directly or indirectly activated by pro-
inflammatory cytokines, were proposed to contribute to the development of cachexia, with 
particular reference to those involved in causing anorexia (see above), lipid depletion, and skeletal 
muscle wasting. 
 Pro-inflammatory cytokines, together with altered production/release of classical hormones 
and/or growth factors, result in a complex network that exerts an inhibitory action on anabolic 
and/or anticatabolic signals, in favor of lipolysis and proteolysis. As an example, muscle wasting, 
increased ubiquitin expression and proteasome enzymatic activity are induced in healthy animals 
by administration of TNF or IL-1 (reviewed in Tisdale, 2008). Consistently, at least in cancer 
cachexia, many years ago few studies demonstrated the crucial role played by cytokines in the 
onset of muscle wasting, showing that loss of muscle mass, protein hypercatabolism and ubiquitin 
hyperexpression could be prevented by treatment of tumor-bearing animals with antibodies 
directed against IL-6, TNF, or IFN (Matthys et al., 1991; Costelli et al., 1993; Strassmann et al., 
1993). Altered cytokine homeostasis, positively correlated with disease progression and mortality 
rates, was reported also in cancer patients (Attard-Montalto et al., 1998; Nakashima et al., 1998). 
Cancer cachexia apart, pro-inflammatory cytokines contribute to muscle wasting also in other 
chronic diseases such as sepsis or AIDS, as well as in aging (see Späte and Schulze, 2004).  
 Pro-inflammatory mediators are likely involved also in pathological states where muscle 
depletion results from the coexistence of protein hypercatabolism and impaired activation of the 
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regenerative response. In this regard, TNF, was shown to impinge on myogenesis with opposite 
outcomes: increased circulating levels appear to inhibit myogenesis (Guttridge et al. 2000; Coletti 
et al. 2002; 2005), while high local concentrations promote regeneration in injured muscles (Chen 
et al. 2005). Reduced stem cell recruitment may contribute to impaired myogenesis (Nicolas et al., 
2005), and TNF was proposed to abrogate satellite cell function, resulting in delayed or impaired 
muscle regeneration in mice after injury (Moresi et al., 2008). Recently, a TNF-dependent, p38- 
regulated epigenetic control of Pax7 expession was identified, directly linking TNF action to the 
inhibition of satellite cell proliferation (Palacios et al., 2010). 
In addition to protein turnover, several cytokines significantly affect lipid metabolism. TNF, 
IL-6, LIF and -INF are known to down-regulate lipoprotein lipase (LPL) activity, thus reducing 
triglyceride storage in adipose tissue, resulting in hyperlipidemia. TNF, in particolar, interferes 
with the synthesis of adipocyte lipogenic enzymes and stimulates triglyceride degradation by 
activating the hormone-sensitive lipase (HSL; van de Woestijne et al., 2011). The relevance of 
these enzymes to the genesis of tissue depletion, at least in cancer cachexia, was recently 
demonstrated by Das and coworkers (2011), showing that tumor growth in mice null for the 
adipose triglyceride lipase (ATGL) or HSL fails to induce both adipose tissue and skeletal muscle 
wasting.  In contrast with the effects exerted on the adipose tissue, TNF increases hepatic 
lipogenesis, contributing to the hyperlipidemia that characterizes cachexia (van de Woestijne et al., 
2011). 
 Finally, the adipose tissue itself produces and releases a huge number of cytokines, termed 
adipokines; they are involved in several physiological processes, including the regulation of lipid 
metabolism, and were shown to play a role also in the pathogenesis of several diseases (Trayhurn 
and Wood, 2004). Among adipokines, leptin and adiponectin deserve particular attention. The 
former,  produced and secreted proportionally to the adipose tissue mass, interferes with the 
regulation of both food intake and energy consumption, by acting on the central control of eating 
(Shan and Yeo, 2011). Physiologically, leptin levels are low and increase in the fasted or fed state, 
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respectively. Other factors, such as inflammation and the mediators involved, may impinge on this 
regulation; in particular, leptin synthesis is increased during acute responses, while decreased in 
chronic inflammation (Popa et al., 2005). Of interest, leptin itself may act as a pro-inflammatory 
cytokine (Lago et al., 2007). As for adiponectin, it is known to potentiate fatty acid oxidation and to 
reduce liver gluconeogenesis, and appears to correlate with body mass index and insulin 
resistance (Lago et al., 2007). In this regard, adiponectin appears to play a role in the protection 
against excess adipose tissue deposition, but also in other pathological states characterized by an 
inflammatory component. Consistently, adiponectin secretion is inhibited by pro-inflammatory 
cytokines (Bruun et al., 2003). At least in cancer cachexia, however, the involvement of adipokines 
appears unlikely. Indeed, leptin plasma levels and expression in the adipose tissue were reported 
to decrease in tumor-bearing animals even in the absence of fat depletion and anorexia (Lopez-
Soriano et al., 1999). Similarly, in gastric cancer patients neither fat loss nor anorexia seem to be 
regulated by leptin (Wallace et al., 1998). Such observations have been confirmed by recent 
evidences showing the lack of correlation between adipokines and markers of inflammation such 
as CRP and IL-6 in patients with non small cell lung cancer (Gulen et al., 2012). However, a 
different view is reported by Kerem and coworkers (2008). 
 
Tissue wasting in cachexia: hypoanabolism or hypercatabolism?  
 The reduction of both adipose tissue and skeletal muscle mass may depend on reduced 
deposition, increased mobilization, or both. In other words, this means that increased rates of 
lipid/protein degradation, reduced rates of synthesis or both are responsible for the changes in 
tissue mass that characterize cachexia in chronic diseases. Increased lipolysis and enhanced 
protein breakdown are generally accepted as hallmarks of cachexia. However, the possible role 
played by a condition of hypoanabolism is less clear. In this regard, for example, muscle protein 
synthesis rates were reported to be reduced, unaltered, or even enhanced in cancer patients (see 
Pisters and Pearlstone, 1993). 
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 Increased lipid mobilization was shown to play a central role in adipose tissue depletion 
associated with cachexia. As an example, high rates of lipolysis (glycerol and free fatty acid 
turnover, lipid oxidation), also in the presence of hyperglycemia, occur in cachectic cancer patients 
(Sakurai and Klein, 1998; Korber et al., 1999). In this regard, both expression and activity levels of 
two lipases (HSL and ATGL) are increased in experimental and human cancer cachexia 
(Agustsonn et al., 2007). In cancer patients, in particular, lipase expression is inversely correlated 
with body mass index (see Bing, 2011). Finally, genetic manipulations aimed at deleting each of 
the two lipases result in restoration of normal adipose tissue mass in tumor-bearing mice (Das et 
al., 2011; see above). Lipolysis-derived fatty acids, through the action of the adipocyte-specific 
gene cell death-inducing DNA fragmentation factor-[alpha]-like effector A (CIDEA), may serve as 
substrates for energy production through oxidation (Laurencikiene et al., 2008).  
 On the other side,  the role played by impaired adipogenesis in cachexia is still to be 
determined. Generally speaking, the occurrence of reduced lipogenesis is generally inferred by the 
observation that the activity of LPL is often inhibited in cachexia (Nara-Ashizawa et al., 2001). 
Similarly, reduced expression of the fatty acid synthase, an enzyme that plays a crucial role in de 
novo lipogenesis,  was reported in rats with adjuvant-induced arthritis, in the absence of increased 
lipolysis (Martin et al., 2008). 
 As for protein metabolism, intracellular proteolysis in the skeletal muscle is operated by 
several systems (see Bonetto, Penna et al., 2009). The autophagic-lysosomal and the proteasomal 
ones are able to degrade proteins into amino acids or small peptides. By contrast, both the Ca2+-
dependent and the caspase pathways, characterized by a restricted catabolic specificity, only lead 
to a limited proteolysis of their substrates. As reported above, several pro-inflammatory cytokines 
were proposed to mediate the induction of protein hypercatabolism. On the other side, anabolism 
is regulated by a complex interplay among amino acids and hormones/growth factors such as 
insulin and IGF-1. In this regard, amino acids, in addition to be necessary for the synthesis of new 
proteins, were shown to interfere with the regulation of mRNA translation (Kadowaki & Kanazawa, 
2003). The stimulation of protein synthesis by anabolic signals such as insulin or IGF-1 results 
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from a transduction pathway involving several kinases such as Akt, phosphoinositide-3-kinase 
(PI3K), glycogen synthase kinase (GSK)-3β, mammalian Target Of Rapamycin (mTOR), and p70 
ribosomal S6 kinase (p70S6K). The pivotal role that this pathway plays in the skeletal muscle results 
clear from observations showing that experimental conditions aimed at enhancing Akt activity, in 
cultured myocytes or in the whole muscle,  lead to a hypertrophic phenotype (Rommel et al., 2001; 
Lai et al., 2004). The other way round, inhibition of this pathway was reported in conditions 
characterized by muscle wasting such as denervation, aging, disuse, or glucocorticoid treatment, 
and its restoration by means of IGF-1 administration or IGF-1 local hyperexpression is able to 
prevent or correct muscle depletion (reviewed in Glass, 2010). An exception, in this regard, is 
experimental cancer cachexia, where the PI3K/Akt/mTOR pathway is not down-regulated 
(Acharrya et al., 2005; Penna, Bonetto et al., 2010), and muscle atrophy cannot be prevented by 
both IGF-1 administration or its hyperexpression in the skeletal muscle (Costelli et al., 2006; 
Penna, Bonetto et al., 2010).  
 On the whole, the observations reported above could support the concept that, cancer 
cachexia apart, hypoanabolism is a relevant factor contributing to muscle depletion. However, 
besides inducing protein synthesis, the PI3K/Akt signaling pathway also down-regulates protein 
catabolism by maintaining in the inactive conformation transcription factors of the FoxO family. 
FoxO3, in particular, regulates both the expression of molecules involved in proteasomal 
degradation, namely the muscle-specific ubiquitin ligase atrogin-1 (Sandri et al., 2004; Stitt et al., 
2004), and the lipidation of LC3, an essential actor in the autophagic-lysosomal proteolysis (Zhao 
et al., 2007). Consistently, FoxO3 deletion results in the protection against muscle wasting in 
experimental models of fasting and denervation atrophy (Zhao et al., 2007). 
 Taking these considerations into account, the question remains opened: is hypoanabolism 
a crucial actor in muscle wasting, or is it just a ‘side-effect’ of the marked hypercatabolic state? The 
question is still more compelling for adipose tissue depletion, since most of the studies address the 
lipolytic side of metabolism, without taking into account the anabolic processes. 
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From mechanistic alterations to therapeutic strategies 
Studies performed on different experimental models have begun to unravel the causative 
factors and the pathophysiological perturbations that underlie cachexia, providing  information 
useful to devise novel antagonist tools. The vast majority of the research in the field of new 
therapies is centered on the treatment of cancer-related cachexia. For this reason, the following 
paragraphs will summarize the state of the art in terms of therapeutic strategies proposed to 
counteract this specific form of body wasting.  
While is obvious, although not precisely an easy task, that the best treatment for cancer 
cachexia would be tumor eradication, to reverse or at least delay cachexia should be one of the 
main goals of therapeutic protocols. Indeed, the occurrence of such syndrome markedly worsens 
patients' quality of life, increases morbidity and mortality, and reduces the tolerance to antiblastic 
treatments (Fallowfield, 2002).  
 
Nutritional interventions 
The maintenance of a good nutritional status in cancer patients is a main goal. Indeed, well-
nourished patients will recover and will tolerate the side-effects of antineoplastic treatments better 
than malnourished ones (Ross et al., 2004). 
Anorexia is the most effectively treatable cachexia-contributing factor (Laviano et al., 2003). 
In this regard, different orexigenic drugs have been proposed (Laviano et al., 2005), among which 
megestrol acetate is the most widely used, although it improves appetite, but not global quality of 
life (Lopez et al., 2004). A comparable effect was shown for corticosteroids, that also control pain 
and reduce nausea and asthenia (Loprinzi et al., 1999), likely in view of their ability to inhibit the 
release of anorexia-inducing cytokines (Patra and Arora, 2012). More recenlty, dronabinol and 
other cannabinoids were proposed to stimulate appetite (Fide et al., 2005), through both a direct 
action on the endocannabinoid receptors, and an indirect one on anorexigenic cytokines (Klein et 
al., 2000; Fide et al., 2005). Finally, gastric cell-derived ghrelin was shown to improve appetite and 
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also to interfere with insulin/IGF-1 dependent pathways (see above); of interest, only anorexic 
cancer patients benefit from ghrelin administration (Neary et al., 2004).  
However, anorexia is just one of the factors contributing to the nutritional status of cancer 
patients. On this line, several tools (fortified normal food, sip food, integrators, nutritional 
supplements, enteral or parenteral nutrition) aimed at supplementing patients' normal diet are 
actually available (Rivadaneira et al., 1998). Nutritional supports generally include functional 
compounds, such as -3 polyunsaturated fatty acids (PUFAs; eicosapentenoic and 
docohesaexaenoic acids), also endowed with anti-inflammatory properties, antioxidants, and 
aminoacids. In this regard, the branched-chain amino acids (BCAA) leucine, isoleucine and valine, 
were shown to exert clinically relevant metabolic effects (Bianchi et al., 2005). BCAA administration 
to cancer patients is reported to result in improved anorexia and energy intake, likely in view of 
their ability to modulate the synthesis of serotonin in the hypothalamus (Cangiano et al., 1996).  
Finally, few years ago, an interesting 'nutritional modulation' approach, based on a rationale 
somewhat opposite to those described above, and for this reason not easily acceptable by the 
clinician community, was proposed by Raffaghello and coworkers (2008, 2010). In order to 
counteract the side-effects of chemotherapeutic treatments, the authors proposed to face the 
metabolic stress occurring after chemotherapy administration by 'preparing' the organism with few 
days of complete starvation (1-2 days before chemotherapy assumption, 1-2 days after). The study 
reports that cancer patients voluntary undergoing starvation refer a marked reduction of side-
effects such as fatigue, weakness, nausea, vomiting, diarrhea (Raffaghello et al., 2010). In 
addition, the same group in a recent report shows that starvation renders tumor cells more prone to 
the cytotoxic effects of chemotherapeutic drugs and that fasting cycles result in delayed tumor 
growth (Lee et al., 2012). The approach proposed would thus result in improved effectiveness of 
antiblastic treatments in face of reduced whole-body toxicity. On this line such a strategy, although 
not directly aimed at counteracting cachexia, could reveal helpful also in this regard, since 
chemotherapy toxicity is now recognized to worsen body wasting in cancer patients (Prado et al., 
2011).  
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Anti-inflammatory strategies 
The interference with the chronic inflammation associated with cachexia was  developed on 
different levels: approaches aimed to down-regulate the inflammatory response in a rather 
unspecific way (corticosteroids, -3 PUFAs, cycloxygenase inhibitors, antioxidants), or strategies 
targeting specific steps of cytokine-dependent signaling (cytokine production, cytokine-receptor 
interaction).  
Among the unspecific approaches, the most relevant is probably the one based on the use 
of  -3 PUFAs. Eicosapentenoic (EPA) and docosaexaenoic (DHA) acid, in particular, are 
endowed with anti-inflammatory properties, being able to reduce the production of pro-
inflammatory cytokines, of molecules deriving from the arachidonic acid cascade (prostaglandins 
and leukotrienes), and of acute phase reactants such as CRP (Laviano et al., 2005; Muscaritoli et 
al., 2006). Tumor-bearing animals treated with EPA show improved body and skeletal muscle 
weight loss and reduced muscle proteasome enzymatic activity. Of interest, EPA treatment also 
results in impaired tumor growth and metastasis (Tisdale et al., 1991; Kimura and Sumiyoshi, 
2005). Most of EPA effects are ascribed to its ability to antagonize the effects of supposed pro-
cachectic factors, namely the lipid mobilizing factor and the proteolysis inducing factor (Tisdale, 
2008).  Consistently, EPA administration to malnourished patients improves body weight loss and 
reduces urinary PIF levels (Barber and Fearon, 2001). These observations, however, were not 
confirmed by a multicenter study on pancreatic cancer patients (Fearon et al., 2003), while another 
report showed that weight gain induced by administration of megestrol acetate is more marked 
than the one obtained with EPA (Jatoi et al., 2004)  Despite these results, a recent systematic 
review shows the beneficial effects of  -3 PUFAs supplementation in cancer, surgical oncology, 
and critical care patients (van der Meij et al., 2011). In particular, -3 PUFAs appears to be mainly 
effective  in terms of quality of life, performance status and physical activity in patients with non-
small cell lung cancer (NSCLC; van der Meij et al., 2012). Finally, EPA-containing nutritional 
supplements may be useful to increase perioperative lean body mass in patients with head and 
neck cancer (Weed et al., 2011). 
16 
 
Another class of compounds endowed with anti-inflammatory properties is represented by 
statins, drugs widely used to treat hypercholesterolemia because of their ability to inhibit the 
hydroxy-methyl glutaryl CoA reductase (Ikeda and Shimada, 1999). Despite this putative anti-
inflammatory effect, however, simvastatin administration to tumor-bearing animals was unable to 
correct cancer-induced body and tissue wasting (Muscaritoli et al., 2003).  
As reported above, specific anti-cytokine strategies may target cytokine synthesis and 
release or their interaction with cell surface receptors. 
Inhibition of cytokine production 
 Cytokine production can be blocked by destabilizing their mRNA or by directly interfere with 
their synthesis or release.  
 Thalidomide, mainly known in the past because of its teratogenicity, affects pro-
inflammatory cytokine mRNA stability (Haslett, 1998), although more recently, a direct effect on the 
transcritpion factor NF-B was also proposed (Wilkes, 2006). A number of clinical trials was set up 
in order to test thalidomide effectiveness in the management of cancer cachexia. Patients with 
metastatic cancer receiving thalidomide showed improvement of quality of life (Bruera et al., 1999), 
weight loss (Khan et al., 2003, Gordon et al., 2005), lean body mass and physical functions 
(Gordon et al., 2005). Finally, a large randomised trial including cachectic cancer patients showed 
that thalidomide alone is less effective that its combination with other treatments (Mantovani, 
2010). More recently an experimental study reported that thalidomide inhibits an E3 ubiquitin ligase 
complex involved in embryonal development (Ito et al., 2010), leading to hypothesize that 
thalidomide effectiveness on muscle wasting in cancer hosts could be achieved through inhibition 
of muscle-specific ubiquitin ligases.  
 However, in addition to teratogenicity, thalidomide has several side-effects such as deep 
venous thrombosis and peripheral neuropathy, constipation, vomiting and drowsiness (BNF, 2009). 
In this regard, a recent report that systematically reviews data on thalidomide treatment in cancer 
cachexia clearly shows that the data available are still too much scanty to draw any significant 
conclusion (Reid et al., 2012). 
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Several phosphodiesterase inhibitors were proposed in order to inhibit cytokine synthesis in 
cachexia, among which pentoxifylline. This drug, in the past used as a hemorheological agent, 
exerts marked anti-inflammatory actions, leading to beneficial effects on cerebral malaria and 
chronic sarcoidosis (Zabel et al., 1997; Das et al., 2003). More recently, it was proposed as a tool 
to treat diabetes (Bryson, 2008). By contrast, data regarding the use of pentoxifylline to treat 
cachexia are quite conflicting. Its administration to tumor-bearing animals prevents muscle atrophy, 
mainly by inhibiting the induction of protein hypercatabolism (Combaret et al., 1999; Costelli et al., 
2002). On the other side, a double-blind, placebo-controlled study showed that pentoxifylline 
administration does not improve anorexia nor induces weight gain (Goldberg et al., 1995).  
Atractylenolide I, a compound isolated from largehead atractylodes rhizome, used by 
Chinese traditional medicine to improve nausea, vomiting and anorexia, was proposed to exert 
anti-inflammatory effects by inhibiting cytokine production (Li et al., 2007). Few years ago it was 
evaluated as an anticachectic agent in a randomized pilot study including gastric cancer patients. 
Both body weight and mid-arm muscle circumference significantly increased with respect to the 
control group, while circulating IL-1 markedly decreased (Liu et al., 2008).  Finally, OHR118, 
a drug endowed with immunomodulatory and cytoprotective properties, is also able to inhibit the 
synthesis of pro-inflammatory chemokines and cytokines. On these basis, a pilot clinical trial was 
designed to assess its usefulness in the management of cancer cachexia. Of the 21 patients 
enrolled, only 11 completed the 2-week study. The results show significant improvements in 
appetite and depression scores, as well as in weight gain maintenance (Chasen et al., 2011).  
Some pro-inflammatory cytokines are synthesized as inactive precursors. This is well 
known for both interlukin (IL)-1 and TNF, proteolytically activated by the IL1-converting enzyme 
(ICE, better known as caspase 1; Thornberry et al., 1992) and the TNF-converting enzyme 
(TACE, or ADAM17; Moss et al., 1997), respectively. Provided that IL-1 is not the most relevant 
cytokine in the pathogenesis of cachexia, most of the studies have concentrated on the search for 
inhibitors to TACE, in order to prevent dangerous increases of TNF  levels. TACE inhibitors, 
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however, never passed phase II clinical trials (for review see Murumkar et al. 2010), and despite a 
couple of them were patented for the treatment of cachexia, no supporting literature is available.  
Interference with cytokine-receptor interaction 
The cytokine-receptor engagement can be disrupted by means of cytokine blocking agents 
(monoclonal antibodies, soluble receptors) or receptor inactivating molecules (receptor antagonists 
or anti-receptor antibodies).  Both groups include molecules commonly used in the clinical practice 
to reduce the inflammatory response in chronic pathologies such as rheumatoid arthritis or Crohn 
disease (anti-TNF monoclonal antibodies, different formulations of soluble TNF-receptor 1 or 2, 
IL-1 receptor antagonist; reviewed in Ghezzi and Cerami, 2005]. The literature reports data about 
the effectiveness of such treatments in preventing body wasting in chronic inflammatory diseases. 
As an example, etanercept (chimeric soluble TNF  receptor 2) or infliximab (anti-TNF 
monoclonal antibody) were reported to increase body weight and lean body mass in patients with 
rheumatoid arthritis (Briot et al., 2005). Such observation however, was not confirmed by a 
different study (Marcora et al., 2006). Only few data are actually available about the effectiveness 
of such kind of drugs in preventing or delaying cancer cachexia. In this regard, anti-TNF 
antibodies, while not an antagonist of IL-1 receptor, proved effective in reducing anorexia, body 
weight loss and protein hypercatabolism in tumor-bearing rats (Costelli et al., 1993; Costelli et al., 
1995). More recently, a clinical trial performed on advanced cancer patients receiving etanercept 
showed the lack of any significant improvement of weight loss, anorexia and survival rate (Jatoi et 
al., 2007). Another clinical trial shows that lean body mass, performance status, quality of life, 
progression-free and overall survival, are not different between pancreatic cancer patients 
receiving gemcitabine alone or gemcitabine plus infliximab (Kishimoto, 1996).  
Other compounds are actually reaching the clinical experimentation. In this regard, an anti-
IL-6 antibody resulted in increased hemoglobinemia and albuminemia in a small phase I trial 
including patients with advanced cancer. CRP levels also tended to reduction, while an apparent 
improvement of hand grip strength and fatigue was reported (Clarke et al., 2009). These 
preliminary results were confirmed by a phase II trial including non small cell lung cancer patients 
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receiving the anti-IL-6 antibody at different doses (Bayliss et al., 2011). An anti-IL-6 receptor 
antibody is also available (Ohtori et al., 2012), however no data are shown in the literature about its 
effectiveness in both experimental and human cancer cachexia. By contrast, another inhibitor of 
the interaction betweeen IL-6 and its receptor, 20S,21-epoxy-resibufogenin-3 acetate, appears to 
prevent carcass weight loss in tumor-bearing mice (Enomoto et al., 2004). 
 
Strategies to correct metabolic alterations 
 Derangements of both protein and lipid metabolism play a crucial role in cachexia, since 
they are directly responsible for the profound tissue wasting that ultimately leads patient to death. 
In this regard, strategies aimed at targeting such alterations, irrespective of the trigger(s) 
reponsible for their occurrence (cytokines, anorexia, oxidative stress), are actively pursued.  
 As for the skeletal muscle, the data collected in the last decade point to deregulation of 
signaling pathways such as those dependent on insulin/IGF-1, MAP-kinases(p38, JNK, and ERK) 
and AMP-kinase as crucial in the onset of the protein hypercatabolic response. The insulin/IGF-1-
dependent signaling, in particular, impinges on both the anabolic and the catabolic side of protein 
turnover (see above). In this regard, induction of this pathway would result in inhibition of protein 
breakdown and stimulation of protein synthesis, likely restoring the normal protein content in the 
wasted muscle. Such a strategy appears to work perfectly well in several experimental models of 
muscle wasting including denervation, amyotrophic lateral sclerosis, disuse (reviewed in Glass, 
2010). However, it is useless in experimental cancer cachexia, where, despite high protein 
breadown rates occur, the insulin/IGF-1 pathway is not down-regulated, protein synthesis rates are 
only slightly reduced or even unchanged, and the protein synthetic signaling is poised into the 
activated state (Costelli et al., 1993; Penna, Bonetto, et al., 2010; Aversa et al., 2012).  
 Increased activation of the MAPKs was reported in different conditions presenting with 
muscle wasting, including aging, diabetes and inflammatory myopathies (reviewed in Glass, 2010). 
In particular, p38 phosphorylation was shown to induce the expression of the ubiquitin ligases 
atrogin-1 and MuRF1, both in vitro and in vivo (Li et al., 2005; Romanello et al., 2010; Liu et al., 
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2011). Activation of p38 was also shown to occur in response to mechanical or electrical 
stimulation, and functional overload of the skeletal muscle (Boppart et al., 2001; Huey, 2006; 
Sakamoto et al., 2003), suggesting that this kinase plays a role in both anabolic and catabolic 
responses. Among the targets of  p38 is MAPK-kinase 2 (MKK2). Its phosphorylation at T317 
allows MKK2 nuclear export in a complex containing p38 itself (Meng et al., 2002). Phosphorylation 
of heat shock protein 27 (HSP27), a substrate of MKK2, is increased in skeletal muscle 
hypertrophy and decreased during atrophy (Huey, 2006; Kawano et al., 2007), while HSP27 
hyperexpression reduces disuse-induced muscle depletion (Dodd et al., 2009). Finally, MKK2 
expression is reduced also in denervation-induced atrophy (Norrby and Tagerud, 2010). The 
occurrence of a cross-talk between MKK2/p38 and PI3K/Akt/mTor pathways was proposed. In this 
regard, the MKK2/p38 complex exported from the nucleus appears to interact with a cytoplasmic 
HSP27/Akt complex (Wu et al., 2007). Similarly to Akt, also MKK2 impinges on both protein 
synthesis and catabolism, by phosphorylating molecules involved in the two pathways (reviewed in 
Rosner et al., 2008). However, despite p38 appears involved in the pathogenesis of muscle 
wasting, no studies demonstrate that its pharmacological inhibition may result in muscle mass 
preservation. Preliminary data show that tumor-bearing mice treated with the p38 inhibitor 
SB203580 are not significantly different from untreated animals in terms of muscle force, food 
intake and tumor mass (Penna et al., 2012).  
 The other MAPK possibly involved in modulating muscle protein content is ERK, although 
its role is still quite controversial. Its inactivation in experimental animals results in muscle atrophy 
(Shi et al., 2009). Not only, it appears able to counteract the anabolic stimuli induced by treatment 
with 2-adrenergic agonists or IGF-1 (Haddad & Adams, 2004; Shi et al., 2007). Consistently, 
reduced levels of active ERK were reported in sarcopenia of aging (Carlson et al., 2009). ERK 
inhibition seems required to increase ubiquitin ligase expression in cultured murine myocytes (Shi 
et al., 2008). By contrast, in the same model system, ERK activation results in reduced myotube 
size (Rommel et al., 1999), while its inhibition leads to a hypertrophic phenotype (Rommel et al., 
1999). Also the IGF-1 protective effects against oxidative-stress myotube damage would involve 
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ERK activity (Yang et al., 2010). Finally, muscle atrophy due to immobilization by hind-limb 
suspension was associated with increased levels of phosphorylated ERK (Kato et al., 2002). As 
IGF-1, also ERK plays a role in myogenesis, being able to enhance the regenerative capacity of 
human satellite cells isolated from both young and old subjects (Carlson et al., 2009). Treatment of 
mice bearing the C26 colon carcinoma with the ERK inhibitor PD98059 partially but significantly 
protects tumor hosts from the onset of body weight loss and muscle mass depletion (Penna et al., 
2010). ERK inhibition also results in normalization of atrogin-1 hyperexpression, independently 
from the state of activation of Akt. In addition, Pax7 expression, a marker of activated satellite cells, 
is significantly increased in the muscle of C26 hosts with respect to controls, while myogenin 
levels, indicative of an ongoing differentiative process, are reduced. Such a pattern likely reflects 
an impairment of muscle regeneration, suggesting that the accumulation of activated satellite cells 
in the muscle of tumor hosts may derive from enhanced proliferation, impaired differentiation, or 
both. However, when tumor bearers are treated with PD98059, Pax7 and myogenin expression is 
restored to control values. These observations suggest that ERK activation likely plays a role in 
maintaining satellite cells in an undifferentiated  state, thus contributing with an additional 
mechanism to muscle depletion (Penna et al., 2010). 
 Finally, AMPK, that mainly works as a sensor of intracellular energetic balance, is also 
involved in the regulation of protein turnover (Mihaylova & Shaw, 2011). AMPK may affect protein 
synthesis mainly in view of its ability to inhibit mTOR-dependent signaling (Mihaylova & Shaw, 
2011), however it was also shown to modulate protein degradation rates, acting on atrogin-1 
expression through a FoxO-dependent mechanism (Nakashima et al., 2007; Romanello et al., 
2010). Of interest, increased AMPK activation is detectable in the skeletal muscle of tumor-bearing 
animals  (Penna, Bonetto et al., 2010; White et al., 2011), where it is associated with marked 
alterations of mitochondrial morphology (Penna et al., unpublished observations).  
 As a conclusion, protein turnover modulations in the skeletal muscle could also be 
counteracted by tools aimed at directly inhibiting the intracellular proteolytic systems. In this regard, 
however, despite encouraging initial observations obtained by treating tumor-bearing animals with 
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inhibitor of lysosomal proteases (Ruff and Secrist, 1984; Tessitore et al., 1994), no significant data 
were obtained.  
 Proteasome inhibitors (bortezomib), currently used for the treatment of some hematologic 
malignancies have severe side-effects, and preliminary data show that they are ineffective in 
preventing muscle wasting in tumor-bearing rats (P. Costelli and M. Muscaritoli, unpublished data). 
Similar observations were obtained by treating tumor-bearing animals with inhibitors of the Ca2+-
dependent proteolytic system (dantrolene; P. Costelli and M. Muscaritoli, unpublished data) or with 
an inhibitor of serine proteases (gabexate mesilate; M. Muscaritoli, unpublished observations). The 
possible explanation for such negative results is that when inhibiting a specific proteolytic system, 
the others likely compensate, eventually resulting in a pattern of muscle wasting. Not only, a note 
of care should be introduced in view of administering inhibitors of the lysosomal proteolysis to 
cachectic subjects. Indeed, tumor-bearing mice with advanced cachexia cannot cope a treatment 
with bafilomycin, suggesting that the autophagic flux blocked by the inhibitor represents a survival 
mechanism (Penna et al., unpublished data).  
 While strategies aimed at blocking muscle protein breakdown are extensively studied, little 
is done in terms of correction of the altered lipid metabolism. This likely arises from the notion that 
skeletal muscle mass is the limiting factor for patient survival (see above). This concept, however, 
should be promptly revised, in view of the results showing that inhibition of lipolytic enzymes in 
tumor-bearing mice reverses the loss muscle mass, in addition to restoring normal adipose depots 
(Das et al., 2011; see above).  
 Little results are avialble in the literature about the use of inhibitors of lipolysis. Recently, 
YC-1, used as an agent against platelet aggregation, was shown to stimulate preadipocyte 
differentiation, to inhibit TNF-induced lipolysis in vitro, and to restore normal circulating level of 
free fatty acids in tumor-bearing mice (Chung et al., 2011).  
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Conclusions  
 The different options proposed to treat cachexia were built up taking into account the 
results obtained from experimental and clinical studies, showing that this syndrome is 
characterized by marked metabolic alterations, mainly due to mediators of both tumor or host 
origin. In addition, such metabolic perturbations are now recognized to occur very early in the 
course of the disease, well before any evidence of general wasting. A number of drugs selected 
because of their effectiveness in preventing experimental cachexia, mostly the cancer-related one, 
are in the pre-clinical phase, or are presently reaching the clinical experimentation. Of particular 
relevance, in this regard, appears the adoption of anti-cytokine strategies, although the results 
available point to combination protocols as the best choice to address the different aspects of 
cachexia (for example, both lipid and protein mass depletion). Moreover, since cachexia often 
becomes clinically evident at a rather advanced disease stage, the detection of early subclinical 
perturbations that may be indicative of a situation of ‘latent cachexia’ (pre-cachexia) is important in 
order to prevent the onset of overt cachexia. The definition of effective therapeutic strategies will 
also reveal useful to improve patients' management and quality of life. 
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